

S1 Fig. Centrally assessed progression-free survival in the Korean population according to treatment with SOX (A) or CAPOX (B). CAPOX, capecitabine plus oxaliplatin; CI, confidence interval; HR, hazard ratio; PFS, progression-free survival; SOX, S-1 (tegafur–gimeracil–oteracil potassium) plus oxaliplatin.